Upstream Processing

Feliza Mirasol is the science editor for 

Articles

Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.

Recombinant Supplements Offer Lower Risk of Cell Culture Contamination

The innovation of single-use technologies is applicable early on in the manufacturing process.

Single-Use Bags Help Maintain Aseptic Ingredient Transfer to Bioreactors

The new facility, which is expected to be operational by spring 2025, will feature 8 x 20,000-L bioreactors with the potential to add further 24 x 20,000-L bioreactors based on market demand.

Fujifilm Chooses North Carolina for New $2-Billion Cell Culture Facility

Using the capabilities of Pharma Waldhof, one of Aceto’s facilities in Düsseldorf, Germany, the company plans to provide customers with access to raw materials, tested products for pharmaceutical cell culture applications, and cell culture media ingredients. 

Aceto Expands Biopharmaceutical and Cell Culture Reagent Portfolio to Meet Customer Demand

Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.

Jumping Seed Train Intensification Hurdles to Maximize Yield

The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.

Fujifilm to Invest Over $2 Billion into US Biopharmaceutical Manufacturing Facility  

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA. 

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center 

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

New EpiMOGRIFY Technology Platform Offers Development Support for Allogeneic Cell Therapies

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Manufacturing, Cell Culture and Fermentation